In this way, preclinical studies have demonstrated that TrkB inhibition has significant favorable effects in animal models regarding neuropathic pain, depression, cancer, and addictive behavior (Ghilardi et al., 2010; Yu and Chen, 2011; Zhou et al., 2017). The gene discussed is NTRK2; the disease is cancer.